Vascular embolic protection and carotid stenting devices
Strategic Profile
In October 2024, the company achieved FDA premarket approval (PMA) for the Neuroguard IEP® System, a unique 3-in-1 carotid stenting system. Contego Medical has raised $66M in funding and operates as a Series D company, positioning itself as a specialist in vascular device innovation with a portfolio of FDA-cleared and CE-marked products.
Cyborg Score Rationale
Contego demonstrates strong regulatory momentum (FDA PMA approval in October 2024) and meaningful clinical validation. The company has secured $66M in Series D funding and maintains an experienced leadership team. However, as a private, smaller competitor in a competitive space facing established incumbents (Medtronic, Abbott), scale and market access remain moderating factors.
Top Insights
Achieved FDA PMA approval (October 2024) for flagship Neuroguard IEP® System after successful PERFORMANCE II clinical trial demonstrating lowest reported 1-year event rates in any adequately powered multicenter carotid revascularization study
Pioneering 3-in-1 integrated design that combines stent, dilation balloon, and embolic filter in single device, reducing procedure steps and improving safety versus traditional systems
Expanded leadership in August 2024 with Chief Medical Officer appointment and prior partnership with Medtronic for exclusive U.S. carotid distribution
Portfolio includes three FDA-cleared systems (Paladin, Vanguard IEP, Excipio SV) and multiple pipeline products in carotid and thrombectomy segments, with expansion into coronary (Corguard) and peripheral vasculature
Named Competitors
Neuroguard (Carotid Stenting) — Carotid stenting and embolic protection systems
Acculink Carotid Stent System — FDA-approved carotid stenting platform
Carotid Stenting Systems — Broad vascular intervention portfolio including carotid systems
Thrombectomy Devices — Thrombectomy and embolic protection platforms
Vascular Embolic Protection — Aortic and vascular intervention devices
Recent Developments
(October 2024) FDA premarket approval (PMA) granted for Neuroguard IEP® System carotid stenting platform
(August 2024) Chief Medical Officer Mitchell J. Silver, D.O., FACC joined to lead clinical strategy and commercialization
(April 2023) Series D funding round completed (amount undisclosed) with expanded investor base
(November 2023) Presented 1-year follow-up results from PERFORMANCE II trial at VIVA conference showing strong safety and efficacy data
Open the full interactive Contego Medical Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.